EI
VKTX icon

EFG International’s Viking Therapeutics VKTX Stock Holding History

EFG International’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Hold
25,658
– – 0.02% 422
2026
Q1 		$835K Sell
25,658
-165
-0.6% -$5.3K 0.02% 429
2025
Q4 		$908K Buy
+25,823
New +$915K 0.02% 390

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

EFG International's VKTX Position: Q2 2026 in Review

EFG International held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 25,658 shares worth $1M. The position accounts for 0.02% of the portfolio, ranked #422.

EFG International first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • EFG International held 25,658 shares of Viking Therapeutics worth $1M as of Q2 2026.
  • EFG International left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.02% of EFG International's portfolio in Q2 2026, its #422 holding.
  • EFG International first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on EFG International's 13F filing for Q2 2026, filed 14 Aug 2026.